Inhibition of PAD4-dependent NETosis phenotype neutralizes IL-17, and studies have shown that the higher IL-17 and PAD4 expression in human pancreatic ductal adenocarcinoma (PDAC), the worse the prognosis, as the higher likelihood of serum NETosis in PDAC patients [77]. Here, IL17A is linked to pancreatic ductal adenocarcinoma.